Nanosomal Irinotecan Targeting Pancreatic Cancer Cell Surface Neuraminidase-1 Sialidase

Area of Science:

• Oncology
• Nanomedicine
• Drug Delivery

Background:

• Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with limited treatment options.
• Current therapies, including immune checkpoint inhibitors, show limited efficacy in PDAC.
• Neuraminidase-1 (Neu-1) is identified as a potential therapeutic target for advanced PDAC.

Purpose of the Study:

• To investigate the potential of nanomedicine targeting Neu-1 for improved chemotherapy in advanced PDAC.
• To evaluate the efficacy and safety of nanosomal irinotecan in preclinical models of PDAC.

Main Methods:

• Development of nanosomes with an inorganic core and phospholipid shell for irinotecan delivery.
• Targeting nanosomes to Neu-1 on cancer cells.
• In vitro studies using Panc-1 cells to assess cytotoxicity and synergistic effects with a Neu-1 inhibitor.
• In vivo studies using a Panc-1 xenograft mouse model to evaluate antitumor efficacy and toxicity.

Main Results:

• Nanosomal irinotecan demonstrated efficient endocytosis and synergistic inhibition of Panc-1 cell growth in vitro (IC50 = 8.07 nm).
• Complete inhibition of tumor growth was observed in the Panc-1 xenograft model with nanosomal irinotecan treatment (5 mg/kg, six doses over 24 days) without significant body weight loss.
• Neu-1 inhibition via nanomedicine enhanced chemotherapy efficacy.

Conclusions:

• Targeting Neu-1 with nanomedicine represents a promising strategy for enhancing chemotherapy in advanced PDAC.
• Nanosomal irinotecan shows significant preclinical efficacy and safety, warranting further investigation for clinical application.
• This approach could improve therapeutic outcomes for patients with advanced pancreatic cancer.